Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10400.18/7331
Título: | Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020 |
Autor: | Rose, Angela Kissling, Esther Emborg, Hanne-Dorthe Larrauri, Amparo McMenamin, Jim Pozo, Francisco Trebbien, Ramona Mazagatos, Clara Whitaker, Heather Machado, Ausenda Gómez, Verónica Nunes, Baltazar Kislaya, Irina Pechirra, Pedro Conde, Patrícia Rodrigues, Ana Paula Cristóvão, Paula Costa, Inês Guiomar, Raquel European IVE Group |
Palavras-chave: | Influenza Influenza vaccine Efectiveness Multicentre Study Test-negative Design Efetividade I-MOVE EuroEVA Gripe Europe Determinantes da Saúde e da Doença Observação e Vigilância Cuidados Saúde Primários Infecções Respiratórias Portugal |
Data: | 12-Mar-2020 |
Editora: | European Centre for Disease Prevention and Control |
Citação: | Euro Surveill. 2020 Mar;25(10):2000153. doi: 10.2807/1560-7917.ES.2020.25.10.2000153 |
Resumo: | Background: Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim: To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods: All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results: There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from −58% to 57% (primary care) and −16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions: Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub) type-specific results across studies. |
Peer review: | yes |
URI: | http://hdl.handle.net/10400.18/7331 |
DOI: | https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000153 |
ISSN: | 1560-7917 |
Versão do Editor: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000153 |
Aparece nas colecções: | DDI - Artigos em revistas internacionais DEP - Artigos em revistas internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
eurosurv-25-10-4.pdf | 637,41 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.